Polypoidal choroidal vasculopathy and treatments
1Department of Ophthalmology, Osaka University Medical School, Osaka, Japan. fgomi@ophthal.med.osaka-u.ac.jp
Insights
Polypoidal choroidal vasculopathy (PCV) is a distinct condition from age-related macular degeneration, with photodynamic therapy showing promise but recurrence impacting long-term vision. Further treatments are needed to inhibit its vascular development.
Area of Science:
- Ophthalmology
- Vascular Biology
- Medical Diagnostics
Background:
- Polypoidal choroidal vasculopathy (PCV) presents unique choroidal vascular abnormalities.
- PCV prevalence is notably higher in Asian populations compared to Caucasians.
Purpose of the Study:
- To review current knowledge on the clinical characteristics of PCV.
- To assess available treatments for PCV.
Main Methods:
- Diagnosis relies heavily on Indocyanine green angiography.
- Comparative efficacy of treatments like photodynamic therapy and bevacizumab was evaluated.
Main Results:
- Photodynamic therapy demonstrates efficacy in treating PCV, with superior 1-year outcomes compared to age-related macular degeneration treatments.
- Recurrence of PCV after photodynamic therapy significantly impacts long-term visual outcomes.
- Bevacizumab shows limited efficacy for PCV.
Conclusions:
- Clinical characteristics and differential responses to treatment suggest PCV is a separate entity from age-related macular degeneration, despite shared genetic factors.
- While photodynamic therapy offers encouraging results for PCV, the risk of recurrence necessitates ongoing monitoring and management.
- Development of novel therapeutic strategies to inhibit the exudative choroidal vasculature in PCV is crucial.
Purpose Of Review:
This review assesses the current knowledge of the clinical characteristics of polypoidal choroidal vasculopathy and treatments.
Recent Findings:
Polypoidal choroidal vasculopathy is a disease with characteristic choroidal vascular abnormalities. Indocyanine green angiography is essential for diagnosis. The prevalence is higher in Asian people than in Caucasians. Photodynamic therapy is efficacious for treating polypoidal choroidal vasculopathy; 1-year results have shown greater benefit of photodynamic therapy than choroidal neovascularization secondary to age-related macular degeneration. Recurrence, however, seriously affects vision long term during follow-up after photodynamic therapy. The lower efficacy of bevacizumab- a full-length antibody of vascular endothelial growth factor- has been shown for polypoidal choroidal vasculopathy.
Summary:
Although the polypoidal choroidal vasculopathy and age-related macular degeneration have been known to share common genetic factors, its clinical characteristics including the different responses to photodynamic therapy suggest that polypoidal choroidal vasculopathy is a separate clinical entity from age-related macular degeneration. The results of photodynamic therapy for polypoidal choroidal vasculopathy are encouraging; however, recurrence may affect vision over time. Therapeutic modalities to inhibit development of the exudative choroidal vasculature of polypoidal choroidal vasculopathy are desirable.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Diabetic Retinopathy
Peripheral Artery Disease III: Interprofessional Care
